CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$12.19
0.57 (4.91%)
▲
5d:
-4.17%
30d:
-15.17%
90d:
-1.85%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $12.19, which is considered fair relative to its 30-day fair value range of $11.76 to $13.45.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.17, while resistance sits at $13.32. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: CTNM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.33 (+92.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.17, while resistance sits at $13.32. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: CTNM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.33 (+92.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.76 -
$13.45
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 92.2% below Wall St target ($22.33)
Trading Range Analysis
30-Day Trading Range
$11.76 -
$13.45
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.71
(22.2%)
Support & Resistance Levels
Support Level
$11.17
Resistance Level
$13.33
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.40
Wall Street Target
$22.33
(+92.2%)
Share & Embed Analysis
Last updated: June 23, 2026 1:42 PM ET
Data refreshes hourly during market hours. Next update: 2:42 PM
Data refreshes hourly during market hours. Next update: 2:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
